Research Article
Cryptococcal Meningitis: A Retrospective Cohort of a Brazilian Reference Hospital in the Post-HAART Era of Universal Access
Table 4
Comparison between induction treatment schemes of 79 patients with cryptococcal meningitis.
| | Variable | AmB + 5-FC | AmB + flu | value | | Mean (range) | Mean (range) |
| | Time, weeks | 2.65 (0.57–14.4) | 2.6 (1–5.43) | — | | AmBd dosea | 50 (20.6–69.1) | 52.4 (50–90) | — | | LFAmB dose | 200 (100–371) | 275 (200–375) | — | | 5-FC dose | 6000 (1280–9800) | — | — | | Flu dose | — | 800 (300–1000) | — | | | (%) | (%) | | | Hypokalemia | (67.0) | (15.1) | — | | Hypomagnesemia | (67.0) | (8.8) | — | | Acute renal injury | (67.0) | (10.1) | — | | Anemia | (67.0) | (12.6) | — | | Flu-consolidation | (51.8) | (15.1) | — | | Time of consolidation, weeks | 8 (1.5–8) | 7.8 (2–8) | — | | 30-day mortality | (11.4) | (26.7) | 0.210 | | 60-day mortality | (17.4) | (26.7) | 0.462 |
|
|
AmB, amphotericin B; 5-FC, flucytosine (mg/day); Flu, fluconazole (mg/day); IQR, interquartile range; AmBd, amphotericin deoxycholate; LFAmb, lipid formulations of amphotericin B. aDose reported in mg/day.
|
